SCHEMBL4396750

SCHEMBL4396750

COc1ccc(CCN2C(=O)/C(=C/c3ccc(-c4ccc(C#N)cc4)o3)SC2=S)cc1OC

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EP300 Q09472 1/20 0.73
CREBBP Q92793 1/20 0.73
MEN1 O00255 4/20 0.63
KMT2A Q03164 4/20 0.63
POLB P06746 3/20 0.63
ALDH1A1 P00352 2/20 0.63
MAPT P10636 2/20 0.63
MAPK1 P28482 2/20 0.63
USP2 O75604 1/20 0.63
L3MBTL1 Q9Y468 1/20 0.63
MAP3K5 Q99683 4/20 0.52
STAT3 P40763 1/20 0.50
PKM P14618 2/20 0.49
MCL1 Q07820 2/20 0.49
PTPN22 Q9Y2R2 2/20 0.49
PTPN7 P35236 1/20 0.49
PTPN12 Q05209 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
HIF1AN Q9NWT6 1/20 0.49
TDP1 Q9NUW8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14025843 1.00 EP300 (0.73) EP300CREBBPMEN1KMT2APOLB
SCHEMBL4396439 1.00 EP300 (0.73) EP300CREBBPMEN1KMT2APOLB
SCHEMBL14045885 0.92 MEN1 (0.63) EP300CREBBPMEN1KMT2APOLB
SCHEMBL4394171 0.87 STAT3 (0.66) EP300CREBBPMEN1KMT2APOLB
SCHEMBL4394189 0.86 MEN1 (0.62) EP300CREBBPMEN1KMT2APOLB
SCHEMBL4394192 0.86 MEN1 (0.62) EP300CREBBPMEN1KMT2APOLB
SCHEMBL13592708 0.86 MEN1 (0.62) EP300CREBBPMEN1KMT2APOLB
SCHEMBL4393928 0.84 EP300 (1.00) EP300CREBBPMEN1KMT2APOLB
SCHEMBL14025836 0.84 EP300 (1.00) EP300CREBBPMEN1KMT2APOLB
SCHEMBL4393931 0.84 EP300 (1.00) EP300CREBBPMEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1830848-B1 USE OF THIAZOLIDINONE DERIVATIVES FOR THE TREATMENT OF SOLID TUMORS CELL THERAPEUTICS EUROPE SRL (IT) 2009-12-16 EP claimed
US-20080261980-A1 Use of Thiazolidinone Derivatives as Antiangiogenic Agents CELL THERAPEUTICS, INC. (US) 2008-10-23 US claimed
EP-1830848-A1 USE OF THIAZOLIDINONE DERIVATIVES AS ANTIANGIOGENIC AGENTS Cell Therapeutics Europe S.R.L. (IT) 2007-09-12 EP claimed
WO-2006066846-A1 USE OF THIAZOLIDINONE DERIVATIVES AS ANTIANGIOGENIC AGENTS CELL THERAPEUTICS EUROPE S.R.L. (IT) 2006-06-29 WO claimed
EP-1830848-B1 USE OF THIAZOLIDINONE DERIVATIVES FOR THE TREATMENT OF SOLID TUMORS CELL THERAPEUTICS EUROPE SRL (IT) 2009-12-16 EP disclosed
US-20080261980-A1 Use of Thiazolidinone Derivatives as Antiangiogenic Agents CELL THERAPEUTICS, INC. (US) 2008-10-23 US disclosed
EP-1830848-A1 USE OF THIAZOLIDINONE DERIVATIVES AS ANTIANGIOGENIC AGENTS Cell Therapeutics Europe S.R.L. (IT) 2007-09-12 EP disclosed
WO-2006066846-A1 USE OF THIAZOLIDINONE DERIVATIVES AS ANTIANGIOGENIC AGENTS CELL THERAPEUTICS EUROPE S.R.L. (IT) 2006-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261980-A1 Use of Thiazolidinone Derivatives as Antiangiogenic Agents EP300, HIF1A, HIF1AN EP300 1/4885CREBBP 10/4885MEN1 2216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.